MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 M3q1NmN6fG:2b4jpZ{BCe3OjeR?= MmS0N{DPxE1? MUG3NkBp NWnNT3ZkTE2VTx?= NG\RVWNKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= MnPoNlA2PzFyNkm=
A431 NIm0NJpMcW6jc3WgRZN{[Xl? MknXOUDPxE1? MUi1JIg> Ml;kSG1UVw>? M4[yUHN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? M2HQcFIxPTdzME[5
HepG2 NFnvWmtEgXSxdH;4bYMhSXO|YYm= M{HCbFExKM7:TR?= MY[yOEBp MVLEUXNQ MWnT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NEHFUHQzOTJyNUmyOS=>
Sk-Hep1 MnHMR5l1d3SxeHnjJGF{e2G7 M3XuWFExKM7:TR?= NV[3N|R6OjRiaB?= M37MSGROW09? MXfT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NIHLR5YzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv5cJo{KM7:TR?= NWPD[YtKPSCm NE[3ZYZFVVOR M1;UV2lEPTB;MD6xOEDPxE1? NISyUmczOTJ6OUK2Oy=>
K1 cells harbored PIK3CA (E542K+/+) NUm1fG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK2cnFIOyEQvF2= NHzl[mM2KGR? MofTSG1UVw>? M{K2TWlEPTB;MD61NkDPxE1? M{flelIyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) M1\iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\VbJhsOyEQvF2= NXTROng{PSCm NHnhR3hFVVOR NGq4[|ZKSzVyPUCuNVgh|ryP NXHFR5FoOjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) M2TpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSzJO69VQ>? NGqyd|g2KGR? MlHRSG1UVw>? MlfCTWM2OD1yLkK3JO69VQ>? NHLvU28zOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NITy[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Th[lMh|ryP Ml\TOUBl NVrCVFJ{TE2VTx?= NHHhdpdKSzVyPUSuOUDPxE1? NX7rTohtOjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CzOlMh|ryP NGnLT4Q2KGR? NXT2THE1TE2VTx?= NX\4XY9sUUN3ME2wMlU6KM7:TR?= M1jxR|IyOjh7Mk[3
Hth74 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrKZWlUOyEQvF2= M4HzSlUh\A>? MV\EUXNQ MnnzTWM2OD1{LkG5JO69VQ>? M2j2R|IyOjh7Mk[3
KAT18 M{\MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPqN{DPxE1? MkXoOUBl MonDSG1UVw>? NFTEfHdKSzVyPUSuOlIh|ryP MUWyNVI5QTJ4Nx?=
SW1736 NGfzZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNFAh|ryP M2TabFUh\A>? M{XmdWROW09? MmjDTWM2OD12Nz61OkDPxE1? M1OwflIyOjh7Mk[3
WRO MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNFAxKM7:TR?= NXvSV5JZPSCm MXzEUXNQ NXzaZlZbUUN3ME6xNFAxKM7:TR?= MX[yNVI5QTJ4Nx?=
TAD2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r4NlExODBizszN NVzGO5o6PSCm NHTRcoVFVVOR M4DkNmlEPTB-MUCwNEDPxE1? MlraNlEzQDl{Nke=
LN229 M1flVmFxd3C2b4Ppd{BCe3OjeR?= M1zOS|AvPSEQvF2= MW[2NEBp MX\EUXNQ MmLqRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? MUGyNlA2PzlzNB?=
T98G M4HOVWFxd3C2b4Ppd{BCe3OjeR?= M3znXFAvPSEQvF2= NFHtRWk3OCCq NV7lcZNNTE2VTx?= M1;pO2F2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk MUWyNlA2PzlzNB?=
HC11 MlTUSpVv[3Srb36gRZN{[Xl? MVWxNEDPxE1? MUmyOEBp MV;EUXNQ MlnXTY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> NHrNPVUzOjR{Nk[yNS=>
MOLT-4 NH\wZ|VEgXSxdH;4bYMhSXO|YYm= MUWxNEDPxE1? NVv0TYtlPDhiaB?= NIi4eIRFVVOR NUC3doxOUUN3ME2xMlfjiIoQvF2= NYTM[HlHOjJ4MUSyOFM>
CEM-R NFvOVpJEgXSxdH;4bYMhSXO|YYm= Mm\yNVAh|ryP M1nldVQ5KGh? MXHEUXNQ NV:0PJFmUUN3ME2zMlPjiIoQvF2= MnG1NlI3OTR{NEO=
CEM-S NX3TdYp7S3m2b4TvfIlkKEG|c3H5 MV6xNEDPxE1? MUG0PEBp M4LyfWROW09? MofKTWM2OD13LkJihKnPxE1? MVKyNlYyPDJ2Mx?=
MOLT-4 MYLGeY5kfGmxbjDBd5NigQ>? NHXFT4oyOCEQvF2= NVvzN3pvOjRiaB?= MmfESG1UVw>? MmfpRoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? M2\KdlIzPjF2MkSz
MOLT-4 NYTMclZSTnWwY4Tpc44hSXO|YYm= M3Pud|TjiIoQvF2= MXm0JIg> Mlm1SG1UVw>? NHrxeWJKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NEnkdpczOjZzNEK0Ny=>
CEM-R M{fu[WZ2dmO2aX;uJGF{e2G7 MUS05qCK|ryP M{Tqb|QhcA>? Mk\1SG1UVw>? NWHXTGc6UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MW[yNlYyPDJ2Mx?=
CEM-S M2HqTGZ2dmO2aX;uJGF{e2G7 MXG05qCK|ryP NGnxV|M1KGh? NF64fm5FVVOR M3zkZ2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MXmyNlYyPDJ2Mx?=
HepG2 cell MVPLbY5ie2ViQYPzZZk> NH3jW3MzOCEQvF2= M2LkZ|I1KGh? M1nobGROW09? NED2ZmVFd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MUCyN|c6PzNzOR?=
HepG2 cell NWrrZYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:zNEDPxE1? MWiyOEBp NYPLO4s2TE2VTx?= NViwbGE{UW6qaXLpeJMh[2WubDDndo94fGh? NE\lfXYzOzd7N{OxPS=>
HepG2 cell MnjxRZBweHSxc3nzJGF{e2G7 M13GbFIxKM7:TR?= NX[0dFNGOjRiaB?= NXe2VGx{TE2VTx?= Mk\YTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{T1[VI{Pzl5M{G5
GEO NVW1TGRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm1NFAhdk1? NUXQWWN3PzJiaB?= NHLkVlJFVVOR NIDVNpNKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NVLB[IhTOjR3OEGyN|E>
CNE-1 NITIR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr1fW5NOTBizszN MkjCPVYhcA>? M2e2[GROW09? M4D1NmlEPTB;Mj65OkDPxE1? M{jVS|I2OzN4OUK1
CNE-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxNEDPxE1? M1T6V|k3KGh? Mkm0SG1UVw>? MUfJR|UxRTRwNUOg{txO M{fPclI2OzN4OUK1
HONE-1 NF6yNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNEDPxE1? NWKzUVV4QTZiaB?= NHeyOmNFVVOR MVrJR|UxRTNwM{eg{txO NI\Nb2YzPTN|NkmyOS=>
SUNE-1 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? MlTuPVYhcA>? NYr2b3RjTE2VTx?= NYK4eZI1UUN3ME2wMlUzKM7:TR?= MonLNlU{OzZ7MkW=
CNE-2 NVH6NlVCTnWwY4Tpc44hSXO|YYm= Ml;ENVAh|ryP NW\zWYlwPDhiaB?= NIXHV3VFVVOR NF3qPJhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MkTJNlU{OzZ7MkW=
HONE-1 NH[2blRHfW6ldHnvckBCe3OjeR?= Ml3uNVAh|ryP MoLZOFghcA>? MmPzSG1UVw>? MVvJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy MWiyOVM{Pjl{NR?=
NEC8 NUDmNnlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfzTWM2OD1yLkC5OlUyKM7:TR?= NIr6bo1USU6JRWK=
P12-ICHIKAWA NFfJT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD1yLkGxOlIh|ryP MmXaV2FPT0WU
MDA-MB-175-VII M1vSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r6SmlEPTB;MD6xN|c{QCEQvF2= NF7uXFBUSU6JRWK=
AsPC-1 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHhTWM2OD1yLkKyNVIzKM7:TR?= NXfYNFliW0GQR1XS
T47D MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMkiyOUDPxE1? Mkf5V2FPT0WU
HH MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfaTWM2OD1yLkOwNlg{KM7:TR?= NH7uVWZUSU6JRWK=
MOLT-16 NXS4Zm1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2OWlEPTB;MD6zNFMzKM7:TR?= NELOUnlUSU6JRWK=
ES5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrFSWRCUUN3ME2wMlM1PDV3IN88US=> Mn2zV2FPT0WU
RS4-11 NFPnN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xb2lEPTB;MD6zOFYyKM7:TR?= NFfpUpZUSU6JRWK=
KARPAS-45 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTaclJKSzVyPUCuN|c{OjFizszN M4Xoc3NCVkeHUh?=
NCI-H720 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PudmlEPTB;MD6zO|Y4QSEQvF2= MYrTRW5ITVJ?
H9 NInsUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq5TWM2OD1yLkO4PFg{KM7:TR?= NXPQRmJ5W0GQR1XS
EFM-19 M1zUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDxR41wUUN3ME2wMlQ1ODFizszN MmnSV2FPT0WU
SBC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fqXmlEPTB;MD60OFA{PSEQvF2= MYDTRW5ITVJ?
A4-Fuk NXvqPGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLITWM2OD1yLkS2PFY5KM7:TR?= MVrTRW5ITVJ?
NCI-H1563 NGnyRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi4PWVKSzVyPUCuOFgyQDlizszN MmC2V2FPT0WU
HCC1419 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwNEi4PVIh|ryP NGeyWHVUSU6JRWK=
H-EMC-SS NGi2Ro9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n4UGlEPTB;MD60PVk{QSEQvF2= M17vO3NCVkeHUh?=
BHT-101 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrNWlEPTB;MD61Nlk3OSEQvF2= NIPid5hUSU6JRWK=
IGROV-1 NX\hdm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliwTWM2OD1yLkW1NlQ6KM7:TR?= NWXh[2ZRW0GQR1XS
HGC-27 NVfIZoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\xTWM2OD1yLkW2O|g{KM7:TR?= NEn2eVNUSU6JRWK=
MDA-MB-361 NILr[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnTTWM2OD1yLkW3O|YyKM7:TR?= Ml;tV2FPT0WU
KE-37 NWT3SVByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPlRlU2UUN3ME2wMlU5OjZizszN M4fjZXNCVkeHUh?=
HCC70 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHK[Y1KSzVyPUCuOVk5OjdizszN NGnBfnRUSU6JRWK=
LNCaP-Clone-FGC MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjzTWM2OD1yLk[xNFQ5KM7:TR?= NEW0S5VUSU6JRWK=
HAL-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rOTGlEPTB;MD62NlE{KM7:TR?= MV\TRW5ITVJ?
HT M2jD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fteGlEPTB;MD62N|I{QSEQvF2= MXnTRW5ITVJ?
MDA-MB-415 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0d2lEPTB;MD62N|YzPiEQvF2= NXTKfY9bW0GQR1XS
NOS-1 NV7XXZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwNkO3NlMh|ryP M{nuOXNCVkeHUh?=
DU-145 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;vfohXUUN3ME2wMlY1PzR3IN88US=> MoXzV2FPT0WU
OCUB-M MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXmTWM2OD1yLkewPVY3KM7:TR?= MUHTRW5ITVJ?
VA-ES-BJ MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTLdWNKSzVyPUCuO|MxOjVizszN NF6wcolUSU6JRWK=
J-RT3-T3-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwN{S0NFMh|ryP MUDTRW5ITVJ?
MOLT-4 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH73dJJKSzVyPUCuPFA2QDJizszN NEj4V5RUSU6JRWK=
NB7 NGLzco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHJR5BKSzVyPUCuPFI1OTFizszN Ml:2V2FPT0WU
L-363 M1XHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDXbFFKSzVyPUCuPFM1PDJizszN M4LRNXNCVkeHUh?=
NKM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWKzUmNSUUN3ME2wMlg3OjV|IN88US=> MWjTRW5ITVJ?
HOP-92 M4jUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfxZoJKSzVyPUCuPFczOjNizszN NHzuTnBUSU6JRWK=
OAW-42 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTMSlVoUUN3ME2wMlg5PzJizszN M2rXN3NCVkeHUh?=
HuO9 NG\wTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P4VGlEPTB;MD65Nlc2OSEQvF2= M3jjVnNCVkeHUh?=
MFE-280 NXXadVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXPb2Q3UUN3ME2wMlk3PDZ3IN88US=> MVjTRW5ITVJ?
EM-2 NYDCTIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz3WWM6UUN3ME2wMlk4QTN7IN88US=> NGLtWJdUSU6JRWK=
NCI-H520 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwOUi1PVIh|ryP NUHBd5g6W0GQR1XS
LB2241-RCC NY\0c4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHjTWM2OD1yLkm5O|M1KM7:TR?= NVvqRZNyW0GQR1XS
SK-NEP-1 M3u3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljtTWM2OD1zLkG0OFg2KM7:TR?= NH[3fplUSU6JRWK=
LXF-289 M1KzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMUexOVYh|ryP MkPBV2FPT0WU
EPLC-272H MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Id3FKSzVyPUGuNVczPTZizszN MX\TRW5ITVJ?
COLO-684 M3radmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkO3NlUh|ryP MUjTRW5ITVJ?
ES1 Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTHTYtyUUN3ME2xMlI1ODZ3IN88US=> NUTTTWd[W0GQR1XS
DOHH-2 M1i4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwMkiyNFMh|ryP Mmf2V2FPT0WU
CTB-1 M3z4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHBT3lKSzVyPUGuNlg6QSEQvF2= M{PWZXNCVkeHUh?=
G-401 NI\1[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDiPJhKSzVyPUGuNlk4QTVizszN MX;TRW5ITVJ?
LoVo Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjS4EzUUN3ME2xMlMzPTN2IN88US=> MkXLV2FPT0WU
Ramos-2G6-4C10 NYrsUFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwM{O3NFEh|ryP M3TkRXNCVkeHUh?=
MFM-223 NYDNSHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX74SI41UUN3ME2xMlM1PDZzIN88US=> NGqwdFdUSU6JRWK=
PA-1 NVj3endYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrUU5VKSzVyPUGuN|UzPjVizszN NF3ndHFUSU6JRWK=
697 NVrhWYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXGTWM2OD1zLkO3OlE3KM7:TR?= NWnkcJk3W0GQR1XS
QIMR-WIL NHz3fVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwNEmxNVYh|ryP M2DLOnNCVkeHUh?=
HOS NHHE[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULNVVVKUUN3ME2xMlQ6PTV6IN88US=> NIPRVWtUSU6JRWK=
DMS-273 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ITWM2OD1zLkWxPVU6KM7:TR?= MVTTRW5ITVJ?
ME-180 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzNFVwUUN3ME2xMlU3QDlzIN88US=> M1jJRnNCVkeHUh?=
HCC2218 NUfHOI9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HuU2lEPTB;MT62PFIzPSEQvF2= MUnTRW5ITVJ?
CAL-54 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\FXmlEPTB;MT63NVI1OiEQvF2= MmrhV2FPT0WU
OMC-1 NH3yfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jHOWlEPTB;MT63OFY4PyEQvF2= MUTTRW5ITVJ?
COR-L105 M1HHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHCTWM2OD1zLke5O|M4KM7:TR?= NIrGTGxUSU6JRWK=
BV-173 NXK3XINPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwOEGwO|Qh|ryP MUjTRW5ITVJ?
RKO MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO3OmlKSzVyPUGuPFcyODFizszN NILHSpNUSU6JRWK=
SNU-387 M{fxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXCU3BZUUN3ME2xMlg5PDB4IN88US=> NIPiT2JUSU6JRWK=
SW1088 NIfxU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonCTWM2OD1zLkm0OlA3KM7:TR?= NGHJRodUSU6JRWK=
Hs-578-T MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwMUG0N|Mh|ryP NUnRPWpGW0GQR1XS
OC-314 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDRTmFKSzVyPUKuNVUxQDZizszN NXLaVmpsW0GQR1XS
RMG-I NULlfmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwMU[zPVgh|ryP NIjWSWlUSU6JRWK=
NCI-H1395 NELPe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwMUiwPVEh|ryP NV3Kd3pzW0GQR1XS
GAMG NXjwOJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nqfGlEPTB;Mj6yN|g1PSEQvF2= MVXTRW5ITVJ?
LB1047-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fQZWlEPTB;Mj6yOFMyPyEQvF2= MXnTRW5ITVJ?
MN-60 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT5TWM2OD1{LkK5PVI{KM7:TR?= MorQV2FPT0WU
OAW-28 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fFWWlEPTB;Mj6yPVk2OSEQvF2= NFrsVGJUSU6JRWK=
NCI-H2228 NG\SVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XIZmlEPTB;Mj6zNVU2OiEQvF2= MX;TRW5ITVJ?
ABC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvnTWM2OD1{LkOzNlU{KM7:TR?= NGDkXHdUSU6JRWK=
LS-513 M4npemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjYTWM2OD1{LkOzOFg1KM7:TR?= MVfTRW5ITVJ?
KS-1 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli5TWM2OD1{LkO4NVkyKM7:TR?= NXXoXXZKW0GQR1XS
NB69 NEHRenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnZU4syUUN3ME2yMlM5QTh|IN88US=> NITFS|RUSU6JRWK=
VM-CUB-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvyNHpKSzVyPUKuN|kxQDNizszN MX7TRW5ITVJ?
D-423MG NIfmVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFezOHBKSzVyPUKuOFExPDRizszN M2XTUXNCVkeHUh?=
EW-18 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XsNWlEPTB;Mj60NVk{QSEQvF2= MVjTRW5ITVJ?
YH-13 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7iVWdCUUN3ME2yMlQ3OTV|IN88US=> NGDxSpJUSU6JRWK=
T-24 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonPTWM2OD1{LkS3PFgyKM7:TR?= M{XK[XNCVkeHUh?=
ES8 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNEmyPFch|ryP MYjTRW5ITVJ?
ES3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD1{LkS5O|U6KM7:TR?= MX7TRW5ITVJ?
RXF393 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDXN3lKSzVyPUKuOlA1QDdizszN NHKz[YJUSU6JRWK=
RPMI-8226 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNkK5OVMh|ryP MWDTRW5ITVJ?
AGS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOzNG1KSzVyPUKuO|IyOzdizszN NHP4XWVUSU6JRWK=
HCC1395 M2ryXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTjTWM2OD1{Lke1NVg4KM7:TR?= MmPuV2FPT0WU
MV-4-11 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwN{WyOlYh|ryP MknLV2FPT0WU
A204 NHHYN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LEfmlEPTB;Mj64N|g4OiEQvF2= NVnPdJk2W0GQR1XS
MCF7 M1e1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljVTWM2OD1{Lki2NVE4KM7:TR?= NWPaS5JwW0GQR1XS
SNU-423 NWH2TmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WxbWlEPTB;Mj64PVI1OiEQvF2= NYTBPIFIW0GQR1XS
NCI-H1048 NEC3OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW0[pZKSzVyPUKuPVY5PjVizszN M1HhU3NCVkeHUh?=
GR-ST NGDqXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nFWmlEPTB;Mz6wOFYyOSEQvF2= NELwZXhUSU6JRWK=
EoL-1- NEKwZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv6TZJuUUN3ME2zMlA4ODV6IN88US=> MWXTRW5ITVJ?
HuH-7 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO1dmw4UUN3ME2zMlA6PDZ2IN88US=> MWDTRW5ITVJ?
OS-RC-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TGcmlEPTB;Mz6xNVE6KM7:TR?= MoXEV2FPT0WU
EW-3 M1P0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMUm1Nlkh|ryP MlnxV2FPT0WU
NCI-H747 NX3h[JlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDNNJlQUUN3ME2zMlIxPjl2IN88US=> NFvCSYhUSU6JRWK=
EW-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwMkG4O|kh|ryP NYHBbW91W0GQR1XS
DOK M4O4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzqWG12UUN3ME2zMlIzQDV7IN88US=> MmP1V2FPT0WU
HCC2157 M{\5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e5cmlEPTB;Mz6zPFE4QSEQvF2= NFrrcGtUSU6JRWK=
OVCAR-3 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nrRmlEPTB;Mz60NFc5PiEQvF2= MV3TRW5ITVJ?
NCI-H1623 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjHTIxKSzVyPUOuOFEzOjRizszN M{n1ZXNCVkeHUh?=
H4 NYexS49GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrZ[FVKSzVyPUOuOFU3OjZizszN M2HjU3NCVkeHUh?=
SW1710 M4LrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNwNE[2O|gh|ryP NHjHeoFUSU6JRWK=
RT-112 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwNUKzPFgh|ryP NGDIPIVUSU6JRWK=
DMS-114 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwNkKyO|gh|ryP Ml7IV2FPT0WU
AN3-CA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXwZ3FqUUN3ME2zMlYzPDV4IN88US=> MnTvV2FPT0WU
KNS-62 M176XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNwNkOzN|gh|ryP NGjoNIRUSU6JRWK=
SJRH30 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TLW2lEPTB;Mz62PVEzOiEQvF2= NHS4WJdUSU6JRWK=
G-402 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;yN2lEPTB;Mz63NFcyOSEQvF2= MoTNV2FPT0WU
MHH-PREB-1 NHLBeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwN{KwN|gh|ryP NWrpfY9ZW0GQR1XS
P30-OHK MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDzOXpKSzVyPUOuPFA6PzZizszN NUL5TG94W0GQR1XS
RVH-421 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTITWM2OD1|LkixO|g5KM7:TR?= MWTTRW5ITVJ?
LU-134-A NIWzVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxRWlEPTB;Mz64PFQzQCEQvF2= NX7mbWpZW0GQR1XS
ECC10 NE\yT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNTWM2OD1|LkmzOlIzKM7:TR?= M1H1XnNCVkeHUh?=
TGW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LRWWlEPTB;ND6wNlMxPSEQvF2= NI[4cVFUSU6JRWK=
MLMA NV3iNpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH2[lcxUUN3ME20MlAzQTZ4IN88US=> MlzJV2FPT0WU
SCC-25 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT5TWM2OD12LkC2OVY3KM7:TR?= NVu0SYY6W0GQR1XS
TYK-nu NFzrOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvGdpJVUUN3ME20MlA6PTN2IN88US=> NYDUNJRXW0GQR1XS
LAMA-84 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwMUSxPVEh|ryP MWPTRW5ITVJ?
Calu-3 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnk[nNKSzVyPUSuNlQ1OTZizszN NYrNXpRqW0GQR1XS
NCI-H460 NEjWXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwMk[0OFMh|ryP NEHjZVhUSU6JRWK=
EGI-1 NIfHOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;MOGlEPTB;ND6zO|c4QCEQvF2= M3;rOHNCVkeHUh?=
NCI-H292 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvJNlV1UUN3ME20MlM5OTR4IN88US=> MWjTRW5ITVJ?
HCE-T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwNEG1O|kh|ryP NF76NnhUSU6JRWK=
EW-11 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvKTWM2OD12LkSxPFM5KM7:TR?= M3Tj[nNCVkeHUh?=
ATN-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojxTWM2OD12LkS0N|A1KM7:TR?= MoXWV2FPT0WU
NB5 M4Lrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jZfWlEPTB;ND61N|Y6PyEQvF2= MoW4V2FPT0WU
KLE MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwN{CxPVgh|ryP NUDmVlRiW0GQR1XS
CAL-39 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD3eWRKSzVyPUSuO|IyPDZizszN MnXZV2FPT0WU
TI-73 NXrTc5ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[0elNJUUN3ME20MlgxPjB7IN88US=> Mni5V2FPT0WU
HO-1-N-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M173d2lEPTB;ND65OFIh|ryP M{CyRnNCVkeHUh?=
786-0 M3u4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLycm1KSzVyPUSuPVQ3PzNizszN MV\TRW5ITVJ?
SK-N-DZ M3y1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPD[5RbUUN3ME20Mlk3OTR{IN88US=> NHPxVlJUSU6JRWK=
NCI-H446 NVHZS3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD13LkKwNFA6KM7:TR?= NInMWYxUSU6JRWK=
ETK-1 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3myfmlEPTB;NT6yNVE3PSEQvF2= M{mz[HNCVkeHUh?=
BT-20 M4LzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTVwMkGzOVMh|ryP NEPuRYlUSU6JRWK=
MEL-HO NIHkN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrp[oRKSzVyPUWuN|c{OzZizszN NHvFcYtUSU6JRWK=
CAL-27 M4\0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W3O2lEPTB;NT60OlM{QSEQvF2= NXTBUWt{W0GQR1XS
SW872 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwNUm0Nlgh|ryP NFvGTFFUSU6JRWK=
RPMI-2650 M1TSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\XeGQzUUN3ME21MlY3OTl7IN88US=> M3zlWXNCVkeHUh?=
PFSK-1 NYXhOWhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT4Onh6UUN3ME21MlczPzN{IN88US=> NGjOUnNUSU6JRWK=
SF295 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwOEC2N|Mh|ryP MmXFV2FPT0WU
Becker MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMWmNKSzVyPUWuPFY1PzJizszN M4LoXnNCVkeHUh?=
Saos-2 M13lVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jO[GlEPTB;NT64OlU{KM7:TR?= M4rUWHNCVkeHUh?=
SK-OV-3 NIPHNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KyVmlEPTB;NT65PVgyPiEQvF2= NHn1fG5USU6JRWK=
VMRC-RCZ NEP4[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLFRnZKSzVyPU[uNFg4PzNizszN NWm4U|NpW0GQR1XS
EW-22 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;F[nRKSzVyPU[uNVk3PDlizszN M2j5enNCVkeHUh?=
BT-474 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPocIlMUUN3ME22MlI{OyEQvF2= MW\TRW5ITVJ?
BFTC-909 M1\hOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lub2lEPTB;Nj6zNFM1PSEQvF2= NWWxUnNzW0GQR1XS
NB12 M33iTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPhcGg5UUN3ME22MlM6ODdzIN88US=> NUTlepFQW0GQR1XS
D-263MG MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwNEWxOlkh|ryP MVHTRW5ITVJ?
SNB75 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rRSGlEPTB;Nj62NFE1OyEQvF2= MX;TRW5ITVJ?
A704 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nGNWlEPTB;Nj62N|A3KM7:TR?= M{K2TXNCVkeHUh?=
NCI-H1693 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILyXY1KSzVyPU[uOlM3ODRizszN NF30fIVUSU6JRWK=
LN-405 NYfCSYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfpb5JKSzVyPU[uO|k3PzJizszN NGe0dGhUSU6JRWK=
CHL-1 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjuTWM2OD14LkiwNFc6KM7:TR?= NF3JcJZUSU6JRWK=
A498 M4HUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfTNHhKSzVyPU[uPFE6PjFizszN Mn\5V2FPT0WU
TE-12 M4rB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[5TWM2OD14LkizPFE4KM7:TR?= NYe2bWVyW0GQR1XS
TE-6 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zZb2lEPTB;Nj65N|A{QCEQvF2= MWrTRW5ITVJ?
AU565 NH7hU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD14Lkm2PVU4KM7:TR?= MkfRV2FPT0WU
RD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTZwOUiyPFQh|ryP Mn;iV2FPT0WU
SW1463 NULOflZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LINmlEPTB;Nz6xNVE3QCEQvF2= MUHTRW5ITVJ?
LU-99A MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf3eFRKSzVyPUeuNVQ{OjJizszN M1\Me3NCVkeHUh?=
NCI-H28 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2TWM2OD15LkK5NlQh|ryP NX\IdmgyW0GQR1XS
MC-IXC NYPZPHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTXTWM2OD15LkS4OVc3KM7:TR?= NU\HfIZxW0GQR1XS
GP5d NHLzeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHr[YxxUUN3ME23MlQ5PzZ2IN88US=> NIryOFFUSU6JRWK=
GB-1 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tVmlEPTB;Nz61OFgxPCEQvF2= M1:4XHNCVkeHUh?=
CAL-33 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwNk[yN|Mh|ryP NYLyOGdVW0GQR1XS
MSTO-211H M1fXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTdwNkezN|Yh|ryP NWX3fXJZW0GQR1XS
TE-5 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHTeFloUUN3ME23Mlc6OzN2IN88US=> NE\tRZdUSU6JRWK=
D-566MG M3ewT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq0RnlpUUN3ME24MlA1PDJ7IN88US=> MnTTV2FPT0WU
JVM-3 NG\LfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\UTWM2OD16LkG1NlY5KM7:TR?= MVTTRW5ITVJ?
T98G NGnM[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XNeGlEPTB;OD6xPFA3PyEQvF2= NWH0NVVCW0GQR1XS
HCC1954 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\MTWM2OD16LkS1NVA1KM7:TR?= NInqbGlUSU6JRWK=
SF126 M1XIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvXdYZUUUN3ME24MlQ2QTN4IN88US=> MXHTRW5ITVJ?
LB996-RCC MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInKT2RKSzVyPUiuOVMzPTdizszN NUnZS2VRW0GQR1XS
SKG-IIIa NGXSTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHHfJd4UUN3ME24MlY{ODZ7IN88US=> M{PjcnNCVkeHUh?=
NCI-SNU-1 NHuwfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH3bpdKSzVyPUiuOlQ3PDNizszN MkOxV2FPT0WU
LB771-HNC NUjmRlI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[2VnBKSzVyPUiuOlQ3QTZizszN M3nyfXNCVkeHUh?=
SCC-4 NUfPV5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3zUIhKSzVyPUiuOlgzOTlizszN NYi3PWd1W0GQR1XS
CAMA-1 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnH[Y1pUUN3ME24Mlc4OTR4IN88US=> NI\yRmhUSU6JRWK=
D-502MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHlUnQ1UUN3ME24Mlc5PjJ7IN88US=> NXjHR|JvW0GQR1XS
ESS-1 NVn2TWtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\WOGIxUUN3ME24Mlg5PzB2IN88US=> M2nwWXNCVkeHUh?=
HEC-1 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJTGlEPTB;OD64PVg3PiEQvF2= M3j4NHNCVkeHUh?=
NB10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTlwMEKyNlQh|ryP NXrWOWRMW0GQR1XS
8505C MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pac2lEPTB;OT6wOFI{OiEQvF2= NUXZTJJYW0GQR1XS
EFO-27 NEnEO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX5TmlKSzVyPUmuNVY1OTJizszN NHXKc|lUSU6JRWK=
HN Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILlfHdKSzVyPUmuNVY3OjhizszN MlvOV2FPT0WU
DSH1 NWXNdJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTXNpZzUUN3ME25MlIxQDdizszN M3frNnNCVkeHUh?=
NBsusSR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\lSWlEPTB;OT6yO|QxOiEQvF2= NVHU[5VuW0GQR1XS
LS-123 M3XoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fTcmlEPTB;OT6zNVc3OSEQvF2= NWrIfWdMW0GQR1XS
SHP-77 NFv6XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTlwM{m5N|Uh|ryP NEfNXXlUSU6JRWK=
ACN NUTGfWdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XjZWlEPTB;OT61N|I4PyEQvF2= NEXCZ3dUSU6JRWK=
U251 NVPFO241T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DCTmlEPTB;OT62OVU1PCEQvF2= NWf3T2VTW0GQR1XS
A431 NWfZXlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH76[YNKSzVyPUmuPFAzOzhizszN NVXpcGxbW0GQR1XS
5637 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK1[JFKSzVyPUmuPFQ6QDRizszN MXXTRW5ITVJ?
MDA-MB-157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHuSY5KSzVyPUmuPVI5PzhizszN NVvXW5o5W0GQR1XS
A101D NV7UR3B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTRTWM2OD17Lkm5PVc1KM7:TR?= M4m4XHNCVkeHUh?=
YKG-1 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\pTWM2OD1zMD6yNFA3KM7:TR?= MXXTRW5ITVJ?
LAN-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjrepZiUUN3ME2xNE4zOTZ2IN88US=> MXjTRW5ITVJ?
OVCAR-5 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFyLkK0N|Mh|ryP MWXTRW5ITVJ?
A549 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy0cVd{UUN3ME2xNE4{QTd|IN88US=> NET5TIdUSU6JRWK=
no-11 NVixNIZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG3T2JKSzVyPUGwMlQ{PTNizszN NGPuc|FUSU6JRWK=
SF539 NEjHUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DOSWlEPTB;MUCuPVA1OSEQvF2= NH3RNGZUSU6JRWK=
A388 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFzLkO4PVch|ryP NV3mT3g6W0GQR1XS
DEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzLkSyOEDPxE1? M{H1[3NCVkeHUh?=
SW954 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTCTWM2OD1zMT60OlY5KM7:TR?= NEfmRlZUSU6JRWK=
TK10 M{[4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTDTWM2OD1zMT61NlcyKM7:TR?= NYP2U2FiW0GQR1XS
SW756 NFr0TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX3TWM2OD1zMT61Nlk1KM7:TR?= NXnRVFF6W0GQR1XS
PC-3 NILtUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrncJpKSzVyPUGxMlU4PjRizszN NUPMZ5lYW0GQR1XS
ONS-76 M4Pye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;QVIdKSzVyPUGxMlY{PiEQvF2= M{LmcnNCVkeHUh?=
A427 M2nmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rqc2lEPTB;MUGuO|A6OyEQvF2= MnK2V2FPT0WU
MEG-01 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLxV5M5UUN3ME2xNU44PTB7IN88US=> M1O1UnNCVkeHUh?=
BB30-HNC NHjyRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[5[2RKSzVyPUGxMlc6QDJizszN M32xOHNCVkeHUh?=
NCI-H1299 NW\oO5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLkiwPVMh|ryP NFLZeJpUSU6JRWK=
GCT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PPWmlEPTB;MUGuPFIzQCEQvF2= M4X2VnNCVkeHUh?=
D-247MG NULyPXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWzcWJKSzVyPUGxMlk3PjNizszN MXnTRW5ITVJ?
CFPAC-1 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m3dmlEPTB;MUGuPVc5OiEQvF2= NEO4W5dUSU6JRWK=
EKVX M4H1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2faUmlEPTB;MUKuNFMyOyEQvF2= MX;TRW5ITVJ?
CAL-51 NV[4NYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Q[WlEPTB;MUKuNFcyPiEQvF2= MUDTRW5ITVJ?
BB49-HNC NHTq[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiUoZKSzVyPUGyMlEyPzdizszN MWXTRW5ITVJ?
RPMI-7951 M1LXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW4fFJKSzVyPUGyMlE5PTRizszN Mn[zV2FPT0WU
RH-1 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132dmlEPTB;MUKuNlE5PCEQvF2= NEPqSG9USU6JRWK=
BCPAP NGfj[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[yepRKUUN3ME2xNk41PzR7IN88US=> MWLTRW5ITVJ?
GCIY MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmwZXo5UUN3ME2xNk42OjB7IN88US=> M1f0WHNCVkeHUh?=
KNS-81-FD NYm4WncxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvWPXh6UUN3ME2xNk42QDZ7IN88US=> MUjTRW5ITVJ?
KYSE-140 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL2TWM2OD1zMj64OVk2KM7:TR?= MnfhV2FPT0WU
Ca-Ski M{fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\sS2lKSzVyPUGyMlkxPDFizszN NFv0R3VUSU6JRWK=
TGBC1TKB NXjNR3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNbIlkUUN3ME2xNk46OTF3IN88US=> NHzaeYhUSU6JRWK=
HCC1187 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPX[HdKSzVyPUGzMlE6OTJizszN NIDaSoJUSU6JRWK=
SJSA-1 NHTmbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Tkc2lEPTB;MUOuNlMzPyEQvF2= NHz6dIRUSU6JRWK=
CTV-1 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH1OplKSzVyPUGzMlM1PSEQvF2= NWDxXZBIW0GQR1XS
WM-115 NVXUR4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewZYxWUUN3ME2xN{43PDh|IN88US=> NGT0UmNUSU6JRWK=
CHP-212 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\4TWM2OD1zMz65O|M6KM7:TR?= MmnJV2FPT0WU
SCC-15 NVjFV3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrZUppjUUN3ME2xN{46Pzd3IN88US=> MojuV2FPT0WU
BPH-1 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XvPWlEPTB;MUSuNVY3PCEQvF2= NXHsRpNXW0GQR1XS
SW780 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO1TWM2OD1zND61NFI2KM7:TR?= Mln0V2FPT0WU
NCI-H2291 M3;neWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF2LkW4O|gh|ryP MX;TRW5ITVJ?
JEG-3 M3vGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvaXWl2UUN3ME2xOE43OzJ4IN88US=> M1y3R3NCVkeHUh?=
CAL-120 NX3OZYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmUlduUUN3ME2xOE44ODJ5IN88US=> NXr3R2hOW0GQR1XS
NCI-H23 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XU[GlEPTB;MUSuO|k6PyEQvF2= NGXGb5pUSU6JRWK=
MS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\xU2lEPTB;MUSuPVYyOSEQvF2= MkWyV2FPT0WU
PC-14 NFvwV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF2Lkm2OVQh|ryP NYixWZplW0GQR1XS
D-283MED NYq3Zo54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF3LkCxNVEh|ryP NXXINW1DW0GQR1XS
OE19 NYnaTY9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF3LkG1OFEh|ryP NF[4WWxUSU6JRWK=
CAS-1 NVfTbllLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\DO3FKSzVyPUG1MlQyQDRizszN NGXrNm1USU6JRWK=
NCI-H727 NH3xdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HwRWlEPTB;MUWuOFIzOSEQvF2= NED2e45USU6JRWK=
SiHa M3n3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vuOWlEPTB;MUWuO|U6PCEQvF2= MoLGV2FPT0WU
BFTC-905 NXLKco1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDcI9KSzVyPUG1Mlc3QTRizszN MXrTRW5ITVJ?
MDA-MB-453 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF4LkG2OFIh|ryP NHG2b3FUSU6JRWK=
HuP-T3 NGGxXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfaWoZKSzVyPUG2MlY{PzNizszN MnLVV2FPT0WU
SK-LU-1 NXzROFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jQTWlEPTB;MU[uOlk2PiEQvF2= MXvTRW5ITVJ?
Detroit562 M17QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF4LkezNVgh|ryP MY\TRW5ITVJ?
HCC1569 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4LkizN|ch|ryP MoPkV2FPT0WU
SK-MES-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XobmlEPTB;MU[uPFQyQSEQvF2= M{K2WnNCVkeHUh?=
BB65-RCC M{DZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHoOItKSzVyPUG3MlA1PzlizszN NH7TS21USU6JRWK=
LOXIMVI NUTVdWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLENXBKSzVyPUG3MlA4ODdizszN NUXvZnNTW0GQR1XS
SW1783 NUTH[WV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LSdmlEPTB;MUeuNVI5KM7:TR?= M3G4R3NCVkeHUh?=
NH-12 NVewNIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkSYdRUUN3ME2xO{4{OzB|IN88US=> M4jSN3NCVkeHUh?=
UACC-257 NVriN3Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfpU2ZxUUN3ME2xO{42PTF{IN88US=> NH7DZnFUSU6JRWK=
KOSC-2 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvzTWM2OD1zNz62O|U4KM7:TR?= MWjTRW5ITVJ?
KG-1 M1rzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvlbVlKSzVyPUG3MlY6OzdizszN MkPXV2FPT0WU
M059J MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5LkewN{DPxE1? MXnTRW5ITVJ?
MHH-NB-11 NYLDeGN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF5Lkm2O|Mh|ryP NYizTFRpW0GQR1XS
EW-1 NXfO[Gx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfGTWM2OD1zOD6xN|gzKM7:TR?= MlrGV2FPT0WU
CAL-85-1 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDjdHdKSzVyPUG4MlI{PTdizszN NXHkeYR4W0GQR1XS
639-V M3Xremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jZ[mlEPTB;MUiuN|M2PCEQvF2= NULWXG55W0GQR1XS
C32 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXXWoVKSzVyPUG4MlQ4OjdizszN NXrCd4NlW0GQR1XS
KM-H2 NV6w[3NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPWb5pLUUN3ME2xPE42OjN{IN88US=> NHLud5JUSU6JRWK=
A253 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj2d2lEUUN3ME2xPE44Ojh4IN88US=> MVfTRW5ITVJ?
NCI-N87 NUO0NFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1zOD65NFA5KM7:TR?= MV\TRW5ITVJ?
8-MG-BA NXfQUWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInPc2tKSzVyPUG5MlA3PDZizszN NI\5UGJUSU6JRWK=
GI-ME-N NH3RepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PEbGlEPTB;MUmuNVU1PiEQvF2= NGSydlhUSU6JRWK=
8305C MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTzPFVKSzVyPUG5MlIzQDZizszN MY\TRW5ITVJ?
TE-8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHJXVlKSzVyPUG5MlMxOjRizszN NU\PZ|ZsW0GQR1XS
KYSE-270 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\vTWM2OD1{MD6wNlE4KM7:TR?= NYDMU4RKW0GQR1XS
HL-60 NF;xUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojrTWM2OD1{MD6wPVQyKM7:TR?= NXfNfmVOW0GQR1XS
Mo-T NXfSd49vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnERnA4UUN3ME2yNE4yPjZ3IN88US=> NWi4UlIyW0GQR1XS
NCI-H1355 NHftOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDnTWM2OD1{MD6zN|c1KM7:TR?= NXWxd|hnW0GQR1XS
HT-1080 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPZXZVKSzVyPUKwMlU1QTdizszN MXfTRW5ITVJ?
MIA-PaCa-2 M3e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjxSotKSzVyPUKwMlY5QDNizszN NXPEe3ZqW0GQR1XS
NCI-H441 NEe0fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzvTWM2OD1{MD63N|c6KM7:TR?= M4X6SnNCVkeHUh?=
LCLC-97TM1 NHn0OldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLPeoNKSzVyPUKwMlgyOzRizszN NVfYVHJTW0GQR1XS
HT-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJzLkW2N|Eh|ryP M{K5OXNCVkeHUh?=
22RV1 NXXpfHp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHsTWM2OD1{MT61Olg2KM7:TR?= NHzpWHhUSU6JRWK=
LK-2 NGHYSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJzLkW5OVMh|ryP NF7Leo9USU6JRWK=
CW-2 NHvMXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfNN3V[UUN3ME2yNU43ODZ7IN88US=> MVPTRW5ITVJ?
KYSE-510 NYPu[XZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO2bVA3UUN3ME2yNU43ODl3IN88US=> M4LvSXNCVkeHUh?=
CGTH-W-1 NVqxRW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJzLkexOlYh|ryP MkLPV2FPT0WU
NCI-H661 M1;6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ{LkCzOEDPxE1? MWjTRW5ITVJ?
KU-19-19 NWTWeZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzPXFVKSzVyPUKyMlE3QTdizszN M{Dye3NCVkeHUh?=
NCI-H2122 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C2OGlEPTB;MkKuNlQ{OiEQvF2= MUTTRW5ITVJ?
NCI-H526 M1Xq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ{LkO4PVUh|ryP MoTpV2FPT0WU
NCI-H1650 NELLZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrKTWM2OD1{Mj63OlQh|ryP NXz6cGlXW0GQR1XS
AM-38 NEHEbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ{Lki2PFkh|ryP MYHTRW5ITVJ?
NCI-H2405 NXy2e2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ|LkK1N|Mh|ryP NV3wZ3RiW0GQR1XS
M14 NELJZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ|LkSwPFgh|ryP NXS3RopXW0GQR1XS
ES4 NX;nfY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJ|LkSyN|Ih|ryP NIK2S25USU6JRWK=
DJM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmzTZlKSzVyPUKzMlUzOzRizszN M1\zfHNCVkeHUh?=
S-117 M1zlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvXcXVKSzVyPUKzMlc3PTFizszN MVLTRW5ITVJ?
MZ2-MEL NV:0OmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\XTWM2OD1{Mz63O|U6KM7:TR?= MkjzV2FPT0WU
SK-MEL-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDUVmNLUUN3ME2yN{45OTN|IN88US=> M1vhdnNCVkeHUh?=
HCC1806 NF;JWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS4TWM2OD1{Mz64O|A6KM7:TR?= NX\JT45NW0GQR1XS
NMC-G1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrUXJZXUUN3ME2yOE4zOjJ4IN88US=> NHjmSlNUSU6JRWK=
DK-MG MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTKZVNKSzVyPUK0MlI6PCEQvF2= NHLXcIFUSU6JRWK=
SK-N-FI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TX[mlEPTB;MkSuN|MxOiEQvF2= NHTESFZUSU6JRWK=
KINGS-1 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zweWlEPTB;MkSuOFg4PCEQvF2= MX\TRW5ITVJ?
HCC2998 NFLXdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETFO4FKSzVyPUK0MlQ5QDVizszN NIT3SYZUSU6JRWK=
ALL-PO MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrkem9DUUN3ME2yOE43OTlizszN MULTRW5ITVJ?
MPP-89 NWDiboZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf3c4xQUUN3ME2yOU4xPDV6IN88US=> Mm\oV2FPT0WU
NCI-H2342 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rmc2lEPTB;MkWuNVk2OyEQvF2= M3X5RnNCVkeHUh?=
TE-1 NUTqN3J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7lTWM2OD1{NT6zOVY{KM7:TR?= M4nWNHNCVkeHUh?=
RH-18 M{mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ3LkW5NVgh|ryP M13IdnNCVkeHUh?=
HT-1376 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITlTGJKSzVyPUK1MlY1PjVizszN Ml7IV2FPT0WU
U-2-OS MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37OSmlEPTB;MkWuOlg5QCEQvF2= Mle1V2FPT0WU
BT-549 NETxZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLOTWM2OD1{NT65NFEyKM7:TR?= NUPtVZlOW0GQR1XS
NCI-H1755 NYrMOoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvKd3hKSzVyPUK1Mlk6PDVizszN NIO5SXdUSU6JRWK=
EW-13 M3LRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjUTG5KSzVyPUK2MlAzPzRizszN NXq1VJZUW0GQR1XS
NB13 M3HiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:0TmlEPTB;Mk[uNFk1QSEQvF2= NYLxNGNEW0GQR1XS
NUGC-3 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrD[W1KSzVyPUK2MlIyODNizszN NEfiXXRUSU6JRWK=
GMS-10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjIO4Z7UUN3ME2yOk4zOzV|IN88US=> MlvWV2FPT0WU
CHP-134 NEHadldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TncGlEPTB;Mk[uN|g3PyEQvF2= MVLTRW5ITVJ?
SW962 M4TmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\nTVBKSzVyPUK2MlUxOjFizszN M1\xU3NCVkeHUh?=
SNU-449 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm5Ro5bUUN3ME2yO{4xQDB|IN88US=> NYjsb4xrW0GQR1XS
HuP-T4 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULpN5JkUUN3ME2yO{4xQDd7IN88US=> Mo\PV2FPT0WU
SW948 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjiR|ZbUUN3ME2yO{4yOzR2IN88US=> MUjTRW5ITVJ?
NCI-H226 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpdmlEPTB;MkeuOFU4QCEQvF2= NWLHNYRzW0GQR1XS
SK-PN-DW M2PsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXPTWM2OD1{Nz62NFEzKM7:TR?= NU\ETItGW0GQR1XS
GI-1 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDoTWM2OD1{Nz63NlEh|ryP MVfTRW5ITVJ?
CAL-12T M{CxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfUSoxKSzVyPUK4MlEyOTJizszN MXjTRW5ITVJ?
YAPC NGTBWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofzTWM2OD1{OD6yOVY1KM7:TR?= M1fGVnNCVkeHUh?=
SNU-C2B MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nWTWlEPTB;MkiuNlk3PCEQvF2= M{DWc3NCVkeHUh?=
RCC10RGB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLSWlKSzVyPUK4MlU1OTdizszN M2jDfXNCVkeHUh?=
ES7 M2D5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfJTWM2OD1{OT6xOFY2KM7:TR?= NHrYT5lUSU6JRWK=
PANC-03-27 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TzO2lEPTB;MkmuOFQ1KM7:TR?= NXnvbY82W0GQR1XS
ES6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPMTWM2OD1{OT64NVU4KM7:TR?= NIrVNYJUSU6JRWK=
HT-1197 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfNfZdvUUN3ME2zNE4xPTl6IN88US=> MnXLV2FPT0WU
ZR-75-30 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S1XGlEPTB;M{CuNlM5OyEQvF2= NUHDdGZTW0GQR1XS
DB M4j4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofITWM2OD1|MD60PVQzKM7:TR?= M1jRWXNCVkeHUh?=
OCI-AML2 NYXK[mg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLnTWM2OD1|MT6wOlkh|ryP NVXHOpRmW0GQR1XS
NCI-H2170 NXrkdVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNzLki1NVYh|ryP MYDTRW5ITVJ?
IST-MES1 NUHhbXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zKbWlEPTB;M{KuNlg6PyEQvF2= MmLtV2FPT0WU
769-P NVT4N4FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGyeHpiUUN3ME2zNk4{PjRzIN88US=> NWfaV3V1W0GQR1XS
COR-L23 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vNOGlEPTB;M{KuPVA4OyEQvF2= NWHoSlZ6W0GQR1XS
SW626 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DvXmlEPTB;M{OuNVc4PiEQvF2= M3vjfHNCVkeHUh?=
LU-139 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rPVWlEPTB;M{OuOlYxPSEQvF2= Ml;FV2FPT0WU
HT-144 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILwT5dKSzVyPUOzMlg3OyEQvF2= NX;6eYJOW0GQR1XS
CaR-1 NUnubYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfXTpdKSzVyPUOzMlk5OjJizszN MlvkV2FPT0WU
OE33 NUTxNHJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTFTWM2OD1|ND6yPFU2KM7:TR?= MUjTRW5ITVJ?
COLO-800 NXPaeo02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUfXhKSzVyPUO0MlM3PDdizszN NFTibllUSU6JRWK=
NB14 NXe2VVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLRTWM2OD1|ND60Olg1KM7:TR?= MnuwV2FPT0WU
KURAMOCHI M4TuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3qTWM2OD1|Nj6xNVk5KM7:TR?= Mn\1V2FPT0WU
SW48 M4izZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN4LkK0O|Qh|ryP NWTme3FuW0GQR1XS
Daoy NF3FZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN4Lk[1N|gh|ryP NIjZZ4RUSU6JRWK=
TGBC24TKB M3fIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\kZmlEPTB;M{[uOlch|ryP NE\FToJUSU6JRWK=
DU-4475 M4\nRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS0TWM2OD1|Nj65NFM{KM7:TR?= M4nyUnNCVkeHUh?=
SW1417 NGHObY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iyNmlEPTB;M{iuNFU2OiEQvF2= MXPTRW5ITVJ?
EFO-21 NWj5dIh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN6LkmzOFkh|ryP M3ftbnNCVkeHUh?=
MG-63 M4HacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN7LkO0NlQh|ryP MXjTRW5ITVJ?
LC-2-ad NFnIUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELpXXlKSzVyPUO5MlU2OTJizszN MoHYV2FPT0WU
NOMO-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxc|ZsUUN3ME2zPU45Ojd2IN88US=> M2HkXXNCVkeHUh?=
COLO-741 NVK1eHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD12MD6xN|A1KM7:TR?= MmjEV2FPT0WU
BxPC-3 NXH2dJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH1TVRiUUN3ME20NE42Pjh4IN88US=> M4fDPHNCVkeHUh?=
HSC-2 NYC1SW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITsRmxKSzVyPUSwMlkyOTNizszN MoLhV2FPT0WU
UMC-11 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRzLkK2N{DPxE1? MkTSV2FPT0WU
HCC1937 NYLXXmhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XGcmlEPTB;NEKuO|g1OyEQvF2= MlLUV2FPT0WU
Calu-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnroTWM2OD12Mz6yN|gzKM7:TR?= NETpbHZUSU6JRWK=
NCI-H1573 M4TpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3vTWM2OD12Mz6zOFc4KM7:TR?= NE\1epBUSU6JRWK=
SK-N-AS M3rhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfTTWM2OD12Mz62NFE6KM7:TR?= MVTTRW5ITVJ?
PSN1 NVrnd45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CzS2lEPTB;NEWuNlU1QCEQvF2= NYO2SohkW0GQR1XS
TE-11 M1zvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;OTWM2OD12NT60PFQzKM7:TR?= MX;TRW5ITVJ?
NCI-H1155 NVGzSWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PuOGlEPTB;NEWuPFk3PyEQvF2= NFHvdWNUSU6JRWK=
KM12 NHfnS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvENolKSzVyPUS1MlkxPzZizszN MnTnV2FPT0WU
RO82-W-1 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ri[mlEPTB;NE[uPVgzOiEQvF2= NH\CfFBUSU6JRWK=
SW1573 NFjaRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f3WmlEPTB;NEeuN|c{PiEQvF2= MXnTRW5ITVJ?
CAKI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fUNWlEPTB;NEiuNlg1PSEQvF2= M3rUcXNCVkeHUh?=
U-118-MG M{Pad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHRNHdKSzVyPUS4MlM4ODJizszN NITlbnZUSU6JRWK=
KYSE-520 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe3R2xKSzVyPUS4MlQxOTZizszN NIn2UWZUSU6JRWK=
HT55 M3S5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHNXWpKSzVyPUS5MlE1PzRizszN M{TC[XNCVkeHUh?=
ChaGo-K-1 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTR7LkS3PVMh|ryP M4fqPHNCVkeHUh?=
IA-LM M1fIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTV2Lk[zNlIh|ryP MW\TRW5ITVJ?
UACC-62 NIrRVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnhPGdKSzVyPUW1MlExPDZizszN MVfTRW5ITVJ?
MKN7 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnmbGpOUUN3ME21Ok4xOjh3IN88US=> MXjTRW5ITVJ?
HPAF-II NYD3OmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\FeYlKSzVyPUW2MlQxPzNizszN NVHlTlBsW0GQR1XS
NTERA-S-cl-D1 M2Hv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTV5Lke3PEDPxE1? NWToPWh3W0GQR1XS
FTC-133 NVrDcGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLoTWM2OD13OD6wPVY6KM7:TR?= M4DYTnNCVkeHUh?=
MHH-ES-1 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj6ZVJKSzVyPUW4MlQ5OTRizszN NGX3PZRUSU6JRWK=
JVM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PUdWlEPTB;NUiuPVUxPiEQvF2= M1fzOXNCVkeHUh?=
TCCSUP MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fxcGlEPTB;NUmuOVI4QSEQvF2= MVvTRW5ITVJ?
COLO-824 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe3TWM2OD14MD6wO|E6KM7:TR?= MVPTRW5ITVJ?
647-V MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\wTWM2OD14MD6xN|Q4KM7:TR?= MW\TRW5ITVJ?
HD-MY-Z NFWyfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWwe5IxUUN3ME22NE42Ojl2IN88US=> MnvhV2FPT0WU
LS-411N MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZzLkO5NFMh|ryP NF:yVW5USU6JRWK=
NCI-H596 NHjJZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLj[JdxUUN3ME22Nk44PDl4IN88US=> NGjlUGRUSU6JRWK=
C-33-A Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:x[npwUUN3ME22OE4xQTV5IN88US=> MVjTRW5ITVJ?
BHY NIH1RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rFVmlEPTB;NkSuNVI1PSEQvF2= MnfoV2FPT0WU
KGN NFrjOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHTdo5KSzVyPU[0MlU2OTRizszN MUXTRW5ITVJ?
NCI-H1092 NYP6XGJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu0doVKSzVyPU[1MlAxQTVizszN MlnDV2FPT0WU
MZ1-PC NVzOSndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M123S2lEPTB;NkWuOVY1QSEQvF2= MmrUV2FPT0WU
LB831-BLC NX30W|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfmdlVKSzVyPU[1Mlg1QDFizszN NVHrR2w2W0GQR1XS
SW620 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD14Nj6yNFM6KM7:TR?= MVHTRW5ITVJ?
HuO-3N1 NEPXfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTZ6LkOyN|gh|ryP NGrZfnpUSU6JRWK=
SK-HEP-1 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZ7Lkm0PFYh|ryP M1\aXnNCVkeHUh?=
LCLC-103H MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqy[IJKSzVyPUewMlY4ODVizszN M2DUVnNCVkeHUh?=
KYSE-70 NH3COoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP5eGliUUN3ME23NE44QDN3IN88US=> MWHTRW5ITVJ?
Mewo Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELRU4VKSzVyPUexMlUxPSEQvF2= MXfTRW5ITVJ?
COLO-668 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LYS2lEPTB;N{GuPFQ2OSEQvF2= MYHTRW5ITVJ?
NCI-H522 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD15Mj6zOFE{KM7:TR?= M4fiT3NCVkeHUh?=
NCI-H1437 M{\lOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXEOXZpUUN3ME23OE41ODR6IN88US=> MVrTRW5ITVJ?
U-266 NYjRSFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fScGlEPTB;N{WuOFUyPiEQvF2= NFTYNpJUSU6JRWK=
MC116 M13JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3YTHVKSzVyPUe1MlU4ODhizszN MofUV2FPT0WU
PANC-10-05 NFzJVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXjfG0yUUN3ME23O{41OjR|IN88US=> M3HvUHNCVkeHUh?=
KYSE-180 NWfyZopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMXWlEPTB;N{euOVQ2PCEQvF2= NFe2XnpUSU6JRWK=
JAR NYnSdJk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e2dWlEPTB;N{muNFU1PiEQvF2= MYHTRW5ITVJ?
CAL-62 NG\GZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRThyLkC5OUDPxE1? M{\3c3NCVkeHUh?=
A3-KAW M3PRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThyLkKxOVQh|ryP NFjhRlNUSU6JRWK=
PANC-08-13 NVXOdZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWxU45KSzVyPUixMlE4PjhizszN MnT4V2FPT0WU
HSC-3 NH\LZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W2VmlEPTB;OEOuN|A4OSEQvF2= MXnTRW5ITVJ?
HTC-C3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPwO2VKSzVyPUizMlQ4ODJizszN MWPTRW5ITVJ?
KY821 NUDwdoNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTh2LkC4PVIh|ryP NETjXHRUSU6JRWK=
DoTc2-4510 M4SyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfHTHBKUUN3ME24OE4zOTh3IN88US=> MYLTRW5ITVJ?
NCI-H1581 NFX0RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTh3LkS2OFEh|ryP NHXndItUSU6JRWK=
KARPAS-299 NELKT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnYVFJKSzVyPUi2MlE6PzdizszN MonrV2FPT0WU
IST-MEL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXnW3pKSzVyPUi2Mlg5PzJizszN MVfTRW5ITVJ?
KP-N-YS Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrhRYNsUUN3ME24PU46ODJ6IN88US=> MYfTRW5ITVJ?
KYSE-410 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrnSldIUUN3ME25NU41ODR{IN88US=> M2\rN3NCVkeHUh?=
TE-10 NU\ROo5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pTWM2OD17MT61OlEyKM7:TR?= MYHTRW5ITVJ?
SK-MEL-1 NYH6XWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL1TWM2OD17Mj65NVA3KM7:TR?= M{TmNnNCVkeHUh?=
COLO-792 NGCwSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DN|lPUUN3ME25OU4zPTZ2IN88US=> MlPYV2FPT0WU
SCH MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3RPGRGUUN3ME25Ok4{QDd5IN88US=> NWTXVHBFW0GQR1XS
NCI-H1792 M{jMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTl4Lki5PVIh|ryP MoHVV2FPT0WU
NCI-H2029 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLPV2RKSzVyPUm2Mlk2PjZizszN MVnTRW5ITVJ?
SW684 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXUcWpCUUN3ME25PE43PjV2IN88US=> NHHaboxUSU6JRWK=
NCI-H209 NGHRUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC2fpRMUUN3ME2xNFAvOTJzIN88US=> M1nzN3NCVkeHUh?=
HLE NIPE[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TFOmlEPTB;MUC1MlI5OiEQvF2= NUXneldtW0GQR1XS
GOTO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFyNz63O|ch|ryP M1TR[nNCVkeHUh?=
NCI-H1793 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFyOT6yPEDPxE1? NXTJSJBKW0GQR1XS
D-392MG NVLmWWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvnSYVyUUN3ME2xNVcvOzl6IN88US=> NX3XV5lXW0GQR1XS
SW1990 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1zMkCuPVUyKM7:TR?= MnnRV2FPT0WU
ML-2 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL2c41RUUN3ME2xNlEvPjd4IN88US=> Mnv0V2FPT0WU
NCI-H2452 M1G4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF{Mj6yNUDPxE1? MnHYV2FPT0WU
SK-MEL-30 NGjDSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5d5dKSzVyPUGyN{4zPDRizszN MWDTRW5ITVJ?
SN12C M1e0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvaOGRKSzVyPUGyOE4yPzZizszN M{TzfHNCVkeHUh?=
NCI-H1770 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{NT61NVQh|ryP MYrTRW5ITVJ?
SF268 NHHYPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\DUlZKSzVyPUGyOk4yPThizszN NITGRYJUSU6JRWK=
BALL-1 M1XBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPGSpZFUUN3ME2xNlYvOjNizszN MnnTV2FPT0WU
COLO-679 M4XLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPW2xJUUN3ME2xNlYvPzV|IN88US=> NIPyNWpUSU6JRWK=
A2780 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO4TWM2OD1zMkiuPVg5KM7:TR?= NEHDWmJUSU6JRWK=
NCI-H1651 MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF|MT6yOFMh|ryP Mn;yV2FPT0WU
NCI-H2087 NYjadI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPnd4E5UUN3ME2xN|EvPDh|IN88US=> NG[0N2xUSU6JRWK=
U-87-MG M{HIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rsUWlEPTB;MUOzMlYxPCEQvF2= M1fnfnNCVkeHUh?=
LB2518-MEL M2nmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLjTWM2OD1zM{WuPVk{KM7:TR?= MoHzV2FPT0WU
HCT-116 NX\5fnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnEfmtKSzVyPUGzO{4zOTdizszN NHPjb25USU6JRWK=
Ca9-22 M3PBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfwVoZ[UUN3ME2xN|kvQDN|IN88US=> MUXTRW5ITVJ?
COR-L88 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWyTWM2OD1zNEKuNVQh|ryP MkPRV2FPT0WU
CP50-MEL-B MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\GcFE3UUN3ME2xOFQvPTBzIN88US=> NH;pTlFUSU6JRWK=
OVCAR-8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF2NT62N|Yh|ryP MnzhV2FPT0WU
SK-MEL-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;iTWM2OD1zNEeuPFc5KM7:TR?= M4TjOXNCVkeHUh?=
GT3TKB NEDTephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD1zNEmuPVI5KM7:TR?= MXfTRW5ITVJ?
KYSE-450 M{HDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXHTWM2OD1zNUGuOVM6KM7:TR?= NGH0OYRUSU6JRWK=
CAPAN-1 M4nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF3Mz6wOlQh|ryP NXnZ[HBmW0GQR1XS
BEN NUDBd|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfPTWM2OD1zNUOuPVI5KM7:TR?= NGrGNIZUSU6JRWK=
NCI-H1304 NEPhN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzW2lEPTB;MUW0MlY6PCEQvF2= MWHTRW5ITVJ?
KU812 NVHxTXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvMTWM2OD1zNUiuOlc1KM7:TR?= Ml7qV2FPT0WU
Capan-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknWTWM2OD1zNkCuOVU{KM7:TR?= NXjBemxLW0GQR1XS
A673 M{Thd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS2blNKSzVyPUG2NU44ODVizszN MXnTRW5ITVJ?
SAS NVPsS4tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV22eWUzUUN3ME2xOlIvPjd6IN88US=> NFS0c5lUSU6JRWK=
NY MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF4NT6zNVQh|ryP MonUV2FPT0WU
HCE-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXXWlEPTB;MU[2Mlg1PSEQvF2= Mn70V2FPT0WU
MDA-MB-231 M33SWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\tTmdKSzVyPUG3O{42ODNizszN M2jYbHNCVkeHUh?=
no-10 NWTkTnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS0bpFKSzVyPUG3PE4yOzRizszN NF70b5pUSU6JRWK=
MZ7-mel NIXaPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHT[Y1GUUN3ME2xO|gvPDZ5IN88US=> MWTTRW5ITVJ?
NCI-H82 NEHwZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5OG4xUUN3ME2xPFAvOTZ3IN88US=> NHLxW4tUSU6JRWK=
CAL-72 M4i2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XzRWlEPTB;MUi1MlA2PCEQvF2= M4jRO3NCVkeHUh?=
NCI-SNU-5 M2jXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjVUndKSzVyPUG4Ok45PCEQvF2= MkLnV2FPT0WU
OVCAR-4 M3y5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnaTWM2OD1zOEiuN|M{KM7:TR?= M3HjXXNCVkeHUh?=
SCC-9 NHLEUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjUcXhyUUN3ME2xPVEh|ryP MYLTRW5ITVJ?
KYSE-150 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOzTWM2OD1zOUGuPFg5KM7:TR?= NGXnN29USU6JRWK=
HT-29 NHrWOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXtTWM2OD1{MEGuNlEzKM7:TR?= NUDCSFFWW0GQR1XS
COLO-678 NVfoSopET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyMT60OUDPxE1? MknzV2FPT0WU
NCI-H650 M1u1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5N2lEPTB;MkCyMlExOyEQvF2= MVnTRW5ITVJ?
HuCCT1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzLeJlKSzVyPUKwOE4zODhizszN Mk\MV2FPT0WU
SW1116 NEfjeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJyNz6wO|ch|ryP MnvJV2FPT0WU
DBTRG-05MG NY\adWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJyNz65NFkh|ryP NXnZVoNEW0GQR1XS
SW982 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Prb2lEPTB;MkC3Mlk1QCEQvF2= NUnuTYZHW0GQR1XS
RCM-1 NVfZTGZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TN[mlEPTB;MkG0Mlc3OiEQvF2= NFe5doJUSU6JRWK=
COLO-320-HSR MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17weWlEPTB;MkG2MlEzPSEQvF2= NVfLWW1KW0GQR1XS
KNS-42 NGPOWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT3TWM2OD1{MU[uOVc1KM7:TR?= NYfkdZdkW0GQR1XS
C2BBe1 NG\pZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2zTWM2OD1{M{GuPVA2KM7:TR?= NYHTd4pJW0GQR1XS
CCRF-CEM MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnX[YZKSzVyPUK0N{44QTVizszN M2HmUHNCVkeHUh?=
SH-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfSfHRlUUN3ME2yOFYvODlizszN MkTFV2FPT0WU
LS-1034 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\XepFmUUN3ME2yOFYvOjZ4IN88US=> MnzHV2FPT0WU
NCI-H2347 M17aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjNbIFKSzVyPUK0O{44OTNizszN NVqzdZpDW0GQR1XS
RPMI-8866 M1fYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjhWJpRUUN3ME2yOFkvOjdizszN M4PvO3NCVkeHUh?=
GAK NGjD[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzETWM2OD1{NUOuNFAzKM7:TR?= M2npVnNCVkeHUh?=
NB6 NXzlRY11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;6fmlEPTB;MkewMlEh|ryP MV7TRW5ITVJ?
COLO-680N M{\DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD1{N{KuOVI4KM7:TR?= MYTTRW5ITVJ?
RERF-LC-MS M4DqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfZTWM2OD1{N{[uNFA4KM7:TR?= MVHTRW5ITVJ?
TGBC11TKB MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMOGZKSzVyPUK3PE4yPzhizszN M13nOHNCVkeHUh?=
C8166 NHLuZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPMUJFKSzVyPUK3PE42ODZizszN NHrpeW9USU6JRWK=
HDLM-2 M1L0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M131eGlEPTB;Mkm0MlQxQSEQvF2= M2CzXHNCVkeHUh?=
IGR-1 M1TzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XITWlEPTB;Mkm1MlY2QSEQvF2= MUPTRW5ITVJ?
FADU NWXaW5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXHOW5KSzVyPUK5O{42OSEQvF2= MoHBV2FPT0WU
L-428 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;UV2lEPTB;Mkm3MlYyPiEQvF2= NW\0T4w{W0GQR1XS
LU-65 M1zodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C1RWlEPTB;M{C0MlMzKM7:TR?= MXrTRW5ITVJ?
HEL NEXGUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNyOT65PFMh|ryP MUDTRW5ITVJ?
NCI-H810 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGxTWM2OD1|MUCuOVch|ryP M2PVUXNCVkeHUh?=
C3A NIXxSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\DfZZKSzVyPUOxNU45ODJizszN NEPpSXdUSU6JRWK=
NCI-H630 NEHFS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X6TWlEPTB;M{OyMlI6PCEQvF2= MnfhV2FPT0WU
KP-N-YN NICzSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLJV4RtUUN3ME2zOFEvOTJ|IN88US=> M1P6R3NCVkeHUh?=
MOLT-13 M{j1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN2Mj6zNlYh|ryP NVzNcYFIW0GQR1XS
NCI-H1993 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[2enZKSzVyPUO0Nk4{PjVizszN M4j0b3NCVkeHUh?=
BE-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN2ND6xOlch|ryP NWfCelNkW0GQR1XS
IST-SL1 M1W5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTtTWM2OD1|NEeuOFAyKM7:TR?= NILyR5JUSU6JRWK=
TE-9 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X1cmlEPTB;M{[zMlU5QSEQvF2= MX\TRW5ITVJ?
LU-135 NYfKVmR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX0b4xTUUN3ME2zOlcvODN3IN88US=> M1foT3NCVkeHUh?=
T84 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjnNWdTUUN3ME2zO|QvPzF{IN88US=> M{njbHNCVkeHUh?=
K-562 NF3EcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX1TWM2OD1|OEOuN|Yh|ryP NW\jfJBkW0GQR1XS
SBC-5 NHfMSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjvUGFkUUN3ME2zPFYvQTh3IN88US=> M3\ZUHNCVkeHUh?=
NB17 M4nU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnFW2VKSzVyPUO5Nk42QTZizszN M13Bb3NCVkeHUh?=
NCI-H2052 NIXaWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjaS|JKSzVyPUO5PE41PzJizszN NVTZUG5xW0GQR1XS
HCC38 NYDTT5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13F[mlEPTB;NECxMlU6OyEQvF2= MUPTRW5ITVJ?
NCI-H69 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS5VXMzUUN3ME20OFEvODh|IN88US=> M2PpZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol
17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Related Antibodies

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID